Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save

Deadline: Sep 7, 2021

Grant amount: Unspecified amount

Fields of work: Microbiomes

Applicant type: Government Entity, Indigenous Group, Organizations

Funding uses: Biomedical

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: Applications are due by 5 pm local time of applicant organization, as follows: 

  • Non-AIDS applications:
    • New: February 5, June 5, October 5
    • Renewal, Resubmission, Revision: March 5, July 5, November 5
  • AIDS and AIDS-related applications:
    • New, Renewal, Resubmission, Revision: May 7, September 7, January 7

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. This FOA will not support phase III clinical trials.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Opportunities

This page was last reviewed August 24, 2018 and last updated August 24, 2018